Skip to main content

Table 2 The baseline characteristics at diagnosis of MDS patients with MF-2/3 (n = 43)

From: Allogeneic stem cell transplantation may overcome the adverse impact of myelofibrosis on the prognosis of myelodysplastic syndrome

  Transplant (n = 20) Non-transplant (n = 23) P
Age (years), median, range 42 (27–60) 58 (21–79) 0.003
Gender, no. (%) 0.106
 Male 10 (50.0%) 17 (73.9%)  
 Female 10 (50.0%) 6 (26.1%)  
Median WBC (range), × 109/L 2.73 (1.10–12.00) 2.91 (1.34–7.36) 0.759
Median NE (range), × 109/L 0.85 (0.04–2.27) 0.92 (0.16–4.92) 0.439
Median HGB (range), g/L 65 (30–138) 69 (36–84) 0.706
Median PLT (range), × 109/L 41.5 (3–234) 82 (8–282) 0.179
MDS subtypes (WHO, 2016), no. (%) 0.290
 MDS-SLD 2 (10.0%) 0 (0.0%)  
 MDS-MLD 3 (15.0%) 1 (4.3%)  
 MDS-RS-SLD 0 (0.0%) 2 (8.7%)  
 MDS-RS-MLD 1 (5.0%) 2 (8.7%)  
 MDS with isolated 5q-deletion 0 (0.0%) 0 (0.0%)  
 MDS-EB-1 5 (25.0%) 5 (21.8%)  
 MDS-EB-2 8 (40.0%) 13 (56.5%)  
 MDS-U 1 (5.0%) 0 (0.0%)  
Cytogenetic 0.692
 Normal karyotype 5 (25.0%) 7 (30.4%)  
 Aberrant karyotype 15 (75.0%) 16 (69.6%)  
IPSS-R risk group, no. (%) 0.128
 Very low 0 (0.0%) 0 (0.0%)  
 Low 2 (10.0%) 3 (13.0%)  
 Intermediate 7 (35.0%) 2 (8.7%)  
 High 6 (30.0%) 6 (26.1%)  
 Very high 5 (25.0%) 12 (52.2%)  
Treatment, no. (%)
 Cytoreductive treatments pre-transplantation 11 (55.0%) 0 (0.0%)  
 Cytoreductive treatments without HSCT 0 (0.0%) 12 (52.2%)  
 Immunoregulatory 0 (0.0%) 5 (21.7%)  
 Supportive care 0 (0.0%) 6 (26.1%)  
Leukemia transformation, no. (%) 6 (30.0%) 2 (8.3%) 0.115
Median time from diagnosis to leukemia transformation, months (range) 7 (1–20) 12 (9–15) 0.249